Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
Authors
Keywords
-
Journal
Journal of Inflammation Research
Volume Volume 16, Issue -, Pages 1471-1478
Publisher
Informa UK Limited
Online
2023-04-06
DOI
10.2147/jir.s397639
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
- (2022) Yoshiya Tanaka et al. Nature Reviews Rheumatology
- Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
- (2022) Patricia Richter et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
- (2021) Przemysław J. Kotyla et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bite of the wolf: innate immune responses propagate autoimmunity in lupus
- (2021) Sarthak Gupta et al. JOURNAL OF CLINICAL INVESTIGATION
- Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
- (2021) Paula Montero et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
- (2021) Sarfaraz A. Hasni et al. Nature Communications
- Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor
- (2021) Qing Yan et al. Frontiers in Immunology
- Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus
- (2021) Jaeseon Lee et al. Frontiers in Immunology
- Treatment of cutaneous lupus erythematosus
- (2020) Hong Shi et al. CURRENT OPINION IN RHEUMATOLOGY
- State‐of‐the‐art treatment of systemic lupus erythematosus
- (2020) Yoshiya Tanaka International Journal of Rheumatic Diseases
- Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions
- (2020) Tanja Fetter et al. Frontiers in Immunology
- JAK Inhibitors: Prospects in Connective Tissue Diseases
- (2020) Hanxiao You et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Translating JAKs to Jakinibs
- (2020) Massimo Gadina et al. JOURNAL OF IMMUNOLOGY
- Janus kinases inhibitors for treating patients with rhupus
- (2020) Cristina Garufi et al. JOINT BONE SPINE
- Kinase inhibition in autoimmunity and inflammation
- (2020) Ali A. Zarrin et al. NATURE REVIEWS DRUG DISCOVERY
- Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation
- (2019) Nick Zimmermann et al. JAMA Dermatology
- Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre
- (2019) Hanxiao You et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update
- (2019) Satoshi Kubo et al. Expert Review of Clinical Immunology
- Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
- (2019) Alessia Alunno et al. Cells
- TheSTAT4SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE
- (2018) Niklas Hagberg et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
- (2018) Qianwen Gao et al. CURRENT DRUG TARGETS
- STAT3 roles in viral infection: antiviral or proviral?
- (2018) Zhangmei Chang et al. Future Virology
- Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
- (2018) Massimo Gadina et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Clinical significance of Janus Kinase inhibitor selectivity
- (2018) Ernest H Choy RHEUMATOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus
- (2016) Joerg Wenzel et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The common γ-chain cytokine receptor: tricks-and-treats for T cells
- (2015) Adam T. Waickman et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model
- (2015) Emilie S. Chan et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
- (2013) Naoko Okiyama et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Overall and Cause-Specific Mortality in Patients With Systemic Lupus Erythematosus: A Meta-Analysis of Observational Studies
- (2013) Marko Yurkovich et al. ARTHRITIS CARE & RESEARCH
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started